Avantor AVTR recently entered into a strategic partnership with BlueWhale Bio to accelerate innovation in CAR-T cell therapy manufacturing. The collaboration merges Avantor’s bioprocessing expertise with BlueWhale’s proprietary Synecta cell-derived nanoparticle (CDNP) technology to streamline cell activation and expansion.
The partnership aims to address key bottlenecks in CAR-T production by enhancing scalability, reducing variability and shortening time-to-patient. Together, the companies plan to deliver next-generation manufacturing solutions that expand patient access and strengthen Avantor’s footprint in the fast-growing cell therapy market.
Likely Trend of AVTR Stock Following the News
Following the announcement, the company's shares traded flat at yesterday’s closing. In the year-to-date period, shares have lost 30.8% against the industry’s 0.5% growth. The S&P 500 has gained 14.5% in the same time frame.
In the long term, the BlueWhale Bio partnership could strengthen Avantor’s position in the high-growth cell and gene therapy market by expanding its portfolio of advanced bioprocessing solutions. By integrating cutting-edge CAR-T manufacturing technologies, Avantor can deepen its presence with biotech and pharma clients, capture higher-margin opportunities in GMP-grade reagents, and drive recurring revenue from next-generation therapy platforms—supporting sustainable growth and long-term shareholder value.
AVTR currently has a market capitalization of $9.46 billion.
Image Source: Zacks Investment Research
More on the Partnership
For Avantor, the partnership with BlueWhale Bio marks a strategic step toward deepening its role in the fast-evolving cell therapy manufacturing landscape. Avantor will leverage its bioprocessing and GMP-grade reagent production capabilities to scale up BlueWhale’s CDNP platform, a breakthrough designed to mimic natural T-cell stimulation. Data from BlueWhale Bio’s preclinical and clinical programs show earlier cell division, higher cell yields, and fewer process interventions, suggesting the potential to shorten CAR-T production time while minimizing cell stress during manufacturing. The technology is already being used in a clinical trial featuring a three-day CAR-T manufacturing process, underscoring its promise for accelerating therapy turnaround and expanding patient access.
This collaboration allows Avantor to integrate cutting-edge activation and expansion reagents into its global manufacturing ecosystem, reinforcing its reputation as a critical enabler of next-generation therapies. By combining its scale, supply reliability, and regulatory expertise with BlueWhale Bio’s scientific innovation, Avantor is well-positioned to deliver a differentiated manufacturing solution for CAR-T developers. Over time, this could enhance Avantor’s presence in high-growth markets, strengthen long-term customer partnerships, and open new avenues for value creation as demand for efficient, scalable cell therapy production continues to rise globally.
Favorable Industry Prospects for AVTR
Per a report by Grand View Research, the global cell and gene therapy manufacturing market size was valued at $7.28 billion in 2022 and is expected to witness a CAGR of 26.6% from 2023 to 2030.
AVTR’s Zacks Rank & Key Picks
Currently, AVTR carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Masimo MASI, Merit Medical System MMSI and West Pharmaceutical Services WST. Each stock presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Masimo shares have lost 10.4% so far this year compared with the industry’s 7.4% decline. Estimates for the company’s 2025 earnings per share have increased 1.3% to $5.30 in the past 30 days.
MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.8%. In the last reported quarter, it posted an earnings surprise of 8.1%.
Estimates for Merit Medical’s 2025 earnings per share have increased 0.8% to $3.63 in the past 60 days. Shares of the company have lost 13.8% so far this year against the industry’s 1.1% growth.
MMSI’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.92%. In the last reported quarter, it delivered an earnings surprise of 17.44%.
Estimates for West Pharmaceutical’s 2025 earnings per share have increased 1.2% to $6.74 in the past 60 days. Shares of the company have lost 18.2% so far this year against the industry’s 1% growth.
WST’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.81%. In the last reported quarter, it delivered an earnings surprise of 21.85%.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpMasimo Corporation (MASI) : Free Stock Analysis Report
Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report
West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report
Avantor, Inc. (AVTR) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
